The Cancer Trial Results That Could Change Care for Millions

A run of late-phase clinical results published this spring marks what may be the most consequential season of oncology data in a generation. Across pancreatic cancer, lung cancer, lymphoma, breast surgery, colorectal cancer, liver cancer, brain metastases, and cancer screening, researchers have recorded survival gains, removed harmful procedures, and broken treatment standards that stood unchallenged for decades. Here is what the evidence actually shows — and why it matters.

A Drug That Doubles Survival in the Deadliest Cancer

Pancreatic cancer kills more than 466,000 people annually worldwide. The five-year survival rate for metastatic disease sits below 3%. For decades, second-line treatment options offered patients months, not milestones — and almost none survived long enough to see them matter.

That baseline has now shifted dramatically. The phase 3 RASolute 302 trial (NCT06625320) tested daraxonrasib — an oral, once-daily RAS(ON) multi-selective inhibitor — against standard chemotherapy in 501 patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The primary results, published in the New England Journal of Medicine, recorded a median overall survival of 13.2 months with daraxonrasib versus 6.7 months with chemotherapy — a 60% reduction in the risk of death (HR 0.40; p < 0.0001).

What makes this result unusual is not just the efficacy but the tolerability. Serious adverse events occurred in 43.6% of daraxonrasib patients versus 57.5% on chemotherapy, and treatment discontinuations due to toxicity were 1.2% versus 11.2%. Patients on the drug also reported significantly slower deterioration in pain and quality of life.

The combination — a near-doubling of survival with a lighter side-effect burden — is unprecedented in randomized PDAC trials. Revolution Medicines has announced plans to file a New Drug Application with the FDA. Brian M. Wolpin, MD, MPH, principal investigator and director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, called the results “a clear and highly meaningful step forward.”

Adjuvant Therapy for RET-Positive Lung Cancer Cuts Recurrence Risk by 83%

For the small but precisely defined group of lung cancer patients whose tumors carry a RET fusion — approximately 1–2% of all non-small cell lung cancer (NSCLC) cases — surgery followed by standard chemotherapy or immunotherapy has historically left up to two-thirds facing recurrence. The phase 3 LIBRETTO-432 trial (NCT04819100) now establishes a new post-surgical standard for this group.

Among 109 patients with stage II–IIIA RET fusion-positive NSCLC, selpercatinib (Retevmo) — an oral RET kinase inhibitor already approved for metastatic disease — reduced the risk of recurrence, progression, or death by 83% relative to placebo (HR 0.172; P = 0.0003). The two-year event-free survival rate was 91.5% versus 61.1% with placebo. Results were published simultaneously in the New England Journal of Medicine.

This positions selpercatinib alongside adjuvant osimertinib and adjuvant alectinib, confirming that the adjuvant targeted therapy model — already proven in EGFR- and ALK-positive disease — extends to RET-driven tumors. Jonathan Goldman, MD, of UCLA and lead study author, described it as the first randomized phase 3 trial of a RET kinase inhibitor in the adjuvant NSCLC setting.

A 25-Year Treatment Ceiling in Lymphoma Finally Falls

For more than two decades, R-CHOP — rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone — has been the unchanged first-line standard for diffuse large B-cell lymphoma (DLBCL). Almost no phase 3 trial in that span has managed to improve on it. The phase 3 frontMIND trial (NCT04824092) changed that.

In 899 patients with high-intermediate or high-risk newly diagnosed DLBCL, adding tafasitamab plus lenalidomide to R-CHOP reduced the risk of progression or death by 25% compared to R-CHOP alone (HR 0.75; P = 0.019). Three-year progression-free survival improved from 60.7% to 67.3%.

Crucially, the benefit held across both ABC-type and GCB-type molecular subtypes of DLBCL — a finding that widens the applicable patient population considerably. Overall survival data remain immature, and serious adverse events were more frequent in the experimental arm (86.7% versus 76.1%). Regulatory submissions are expected to follow. Lead investigator Georg Lenz, MD, PhD, of University Hospital Münster, has described the combination as a potential new frontline standard for high-risk large B-cell lymphoma.

Breast Cancer Surgery: Removing Lymph Nodes Was Causing Harm Without Helping

For decades, detecting cancer in sentinel lymph nodes during breast surgery automatically triggered axillary lymph node dissection (ALND) — removal of additional lymph nodes from the armpit, a procedure associated with persistent arm swelling, pain, and reduced function. Long-term data from the phase 3 SENOMAC trial (NCT02240472), published in the Journal of Clinical Oncology, now show conclusively that skipping ALND is safe — and meaningfully better for patients.

Across 2,540 patients followed for a median of 60.1 months, five-year overall survival was 94.4% in the omission group versus 93.4% with ALND (HR 0.89; non-inferiority P < 0.001). There was no survival difference — but there was a meaningful quality-of-life difference. EORTC arm symptom scores were worse in the ALND group at every timepoint: the average difference favoring omission was 10.90 points at one year, 9.86 at three years, and 10.02 at five years.

More than one-third of participants underwent mastectomy — a population historically absent from earlier omission trials — making the result more broadly applicable than any prior data. Lead author Jana de Boniface, MD, PhD, of Karolinska Institutet, has stated she expects current guidelines to be updated accordingly: “axillary surgery should be seen as a diagnostic instrument, not a therapeutic tool.”

Three More Meaningful Advances: Colorectal, Liver, and Brain

Across three additional cancer types, this spring’s data delivered results that shift or redefine current standards of care:

• Colorectal cancer (BRAF V600E): The BREAKWATER trial added encorafenib plus cetuximab to standard first-line chemotherapy (FOLFOX or FOLFIRI) in BRAF V600E-mutant metastatic colorectal cancer — a subgroup representing approximately 8–10% of metastatic cases with historically poor prognosis. Both progression-free and overall survival improved, earning FDA traditional approval. This is the first regimen to improve first-line outcomes specifically in this molecularly defined population.
• Liver cancer (HCC): The phase 3 EMERALD-3 trial tested adding dual immunotherapy — the PD-L1 inhibitor durvalumab plus the CTLA-4 inhibitor tremelimumab — to transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma. Both progression-free and overall survival favored the combination over TACE alone, potentially redefining the locoregional standard of care for this stage of the disease.
• Brain metastases (intraoperative radiation): The phase 3 ROADS trial (NCT04365374) compared implanting radioactive cesium-131 tiles directly into the surgical cavity after resection of large brain metastases (2–7 cm) against post-operative stereotactic radiotherapy. Local recurrence at the surgical site fell by 94% with the tile approach (1% vs. 12%), and two-year overall survival reached 61.7% versus 35.7%. Rates of serious adverse events and radiation necrosis did not differ significantly — a combination of substantially better efficacy with no added toxicity.

 Cancer Screening: A Promising Signal That Doesn’t Yet Change Guidelines

The NHS-Galleri trial (NCT05611632) is the largest randomized controlled trial of any cancer screening technology in history: 142,942 asymptomatic adults aged 50–77 across England, screened annually for three years with GRAIL’s Galleri multi-cancer early detection blood test. The results are genuinely mixed — and honest about it.

The trial did not meet its primary endpoint: a reduction in stage III and IV diagnoses across 12 prespecified cancer types. But several secondary findings have generated significant clinical attention:

•   Stage IV diagnoses fell by 14% and stage I–III diagnoses rose by 19% in the Galleri group
•   Cancer detection through screening was four times higher in the Galleri group than in standard care (1,173 vs. 290 cases)
•   Emergency cancer presentations fell 20%
•   Test specificity reached 99.55% with a positive predictive value of 52%

 The effect on stage IV cancers strengthened through the third year of screening. Professor Charles Swanton, thoracic medical oncologist at University College London Hospital and one of the trial’s chief investigators, acknowledged the primary endpoint was not met while noting the pre-specified secondary finding of more than 20% reduction in stage IV cancers.

The test is not ready for widespread recommendation. Survival benefit data remain pending, overdiagnosis questions are unresolved, and the trial’s long-term follow-up continues. What the NHS-Galleri data do show is that the signal is real enough to keep watching closely.

What This Season of Data Actually Means

Not every result carries equal weight. The daraxonrasib data in pancreatic cancer represent a landmark by any standard — the largest survival improvement ever recorded in a randomized second-line PDAC trial. LIBRETTO-432 establishes a new adjuvant standard in a molecularly defined lung cancer subgroup. frontMIND breaks a 25-year ceiling in DLBCL. SENOMAC removes a surgery that was causing measurable harm without improving survival. The NHS-Galleri result is genuinely uncertain: promising enough to monitor, not yet proven enough to act on.

The broader pattern is precision — each advance is tied to a specific molecular marker, patient subset, or clinical context. The science is clearly moving. What follows is the harder question: whether healthcare systems can identify which patients qualify, afford the agents involved, and implement the changes in time for patients who need them now.

Author

Bernice Lottering

Related Post

Oncology Insights

Two Left-Field Trials and the Industry Undercurrents Running Through ASCO 2026

2026-05-27

Precision Medicines

Abbott Completes Exact Sciences Acquisition to Transform Global Cancer Diagnostics

2026-03-23

Regional

The Middle East’s 2026 Clinical Trial Readouts: Will Research Deliver Results?

2026-02-12